Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2004 May;70(5) > Minerva Anestesiologica 2004 May;70(5):365-71

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,623


eTOC

 

SEPSIS  SMART 2004 - Milan, May 12-14, 2004FREEfree


Minerva Anestesiologica 2004 May;70(5):365-71

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English

Ethyl pyruvate: a novel treatment for sepsis and shock

Fink M. P.

Department of Critical Care Medicine, University of Pittsburgh Medical School


FULL TEXT  


Pyruvic acid is a simple 3 carbon α-keto-monocarboxylic acid. Recognition that pyruvate is an effective scavenger of reactive oxygen species (ROS) prompted investigators to use it as therapeutic agent for various pathological conditions that are thought to be mediated by redox dependent phenomena, like myocardial, intestinal or hepatic ischemia/reperfusion-induced injury. Ethyl Pyruvate showed to be more effective and safer than equimolar doses of sodium pyruvate. Ethyl Pyruvate showed to have anti-inflammatory effects. In animal models Ethyl Pyruvate improved hyperpermeability and bacterial translocation due to endotoxemia and improved the development of renal disfunction as well as some of the morphological findings of kidney injury. The farmacological basis for the anti-inflammatory effects of EP remains to be explained. It is plausible that EP mediates suppression of NF-KB activation and secrection of NO and of pro-inflammatory cytokines.

top of page

Publication History

Cite this article as

Corresponding author e-mail